陈爽;张红梅;

• 1:国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院影像诊断科

摘要(Abstract)：

肝内胆管细胞癌(intrahepatic cholangiocarcinoma,ICC)是仅次于肝细胞癌的肝脏原发恶性肿瘤，近几年发病率逐渐增加。根据大体形态和生长方式，可将ICC分为肿块型、胆管内生长型和沿胆管浸润型，其中以肝内肿块型胆管细胞癌(intrahepatic mass-forming cholangiocarcinoma,IMCC)最常见。由于治疗方式和预后表现有别于其他肝脏恶性肿瘤，因此，较早且较准确的诊断对选择最佳的治疗具有重要意义。MRI目前是治疗前对ICC进行诊断、分期和预后评估的首选影像检查方法。尤其是多模态MRI技术，可以综合各模态的优点，反映肿瘤组织微观结构的改变，有助于肿瘤的定性诊断及肿瘤微环境的评估，从而间接反映肿瘤的恶性程度、浸润范围等与预后相关的一系列特征。常用的多模态MRI技术包括扩散加权成像、动态对比增强磁共振成像等。现对多模态MRI的不同技术及其在ICC的研究进展进行综述。

关键词(KeyWords)： 多模态磁共振成像;扩散加权成像;动态对比增强磁共振成像;肝内肿块型胆管细胞癌;诊断;预后

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 陈爽;张红梅;

参考文献(References)：

• [1]Sarcognato S,Sacchi D,Fassan M,et al.Cholangiocarcinoma[J].Pathologica,2021,113(3):158-169.DOI:10.32074/1591-951X-252.
• [2]Banales JM,Marin JJG,Lamarca A,et al.Cholangiocarcinoma 2020:the next horizon in mechanisms and management[J].Nat Rev Gastroenterol Hepatol,2020,17(9):557-588.DOI:10.1038/s41575-020-0310-z.
• [3]Chiow SM,Khoo HW,Low JK,et al.Imaging mimickers of cholangiocarcinoma:a pictorial review[J].Abdom Radiol (NY),2022,47(3):981-997.DOI:10.1007/s00261-021-03399-9.
• [4]Seo N,Kim DY,Choi JY.Cross-sectional imaging of intrahepatic cholangiocarcinoma:development,growth,spread,and prognosis[J].AJRAm J Roentgenol,2017,209(2):W64-W75.DOI:10.2214/AJR.16.16923.
• [5]Machairas N,Lang H,Jayant K,et al.Intrahepatic cholangiocarcinoma:limitations for resectability,current surgical concepts and future perspectives[J].Eur J Surg Oncol,2020,46(5):740-746.DOI:10.1016/j.ejso.2020.01.028.
• [6]Li Q,Wei Y,Che F,et al.Multiparametric magnetic resonance imaging improves the prognostic outcomes in patients with intrahepatic cholangiocarcinoma after curative-intent resection[J].Front Oncol,2022,12:756726.DOI:10.3389/fonc.2022.756726.
• [7]Tsilimigras DI,Sahara K,Wu L,et al.Very early recurrence after liver resection for intrahepatic cholangiocarcinoma[J].JAMA Surg,2020,155(9):823.DOI:10.1001/jamasurg.2020.1973.
• [8]Entezari P,Riaz A.Intrahepatic cholangiocarcinoma[J].Semin Intervent Radiol,2020,37(5):475-483.DOI:10.1055/s-0040-1719188.
• [9]Granata V,Grassi R,Fusco R,et al.Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI:how radiologist should assess MRfeatures[J].La Radiol Med,2021,126(12):1584-1600.DOI:10.1007/s11547-021-01428-7.
• [10]Kim YY,Yeom SK,Shin H,et al.Clinical staging of mass-forming intrahepatic cholangiocarcinoma:computed tomography versus magnetic resonance imaging[J].Hepatol Commun,2021,5(12):2009-2018.DOI:10.1002/hep4.1774.
• [11]Saleh M,Virarkar M,Bura V,et al.Intrahepatic cholangiocarcinoma:pathogenesis,current staging,and radiological findings[J].Abdom Radiol(NY),2020,45(11):3662-3680.DOI:10.1007/s00261-020-02559-7.
• [12]Sha M,Jeong S,Qiu BJ,et al.Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma[J].Cancer Med,2018,7(9):4665-4677.DOI:10.1002/cam4.1704.
• [13]Kova\u010d JD,Jankovi\u0107 A,\u0110iki\u0107-Rom A,et al.Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers:how to differentiate them using MRI[J].Curr Oncol,2022,29(2):698-723.DOI:10.3390/curroncol29020061.
• [14]Rhee H,Choi SH,Park JH,et al.Preoperative magnetic resonance imaging-based prognostic model for mass-forming intrahepatic cholangiocarcinoma[J].Liver Int,2022,42(4):930-941.DOI:10.1111/liv.15196.
• [15]Mao YF,Zhu Y,Qiu YD,et al.Predicting peritumoral Glisson's sheath invasion of intrahepatic cholangiocarcinoma with preoperative CTimaging[J].Quant Imaging Med Surg,2019,9(2):219-229.DOI:10.21037/qims.2018.12.11.
• [16]Kim DH,Choi SH,Park SH,et al.The Liver Imaging Reporting and Data System tumor-in-vein category:a systematic review and meta-analysis[J].Eur Radiol,2021,31(4):2497-2506.DOI:10.1007/s00330-020-07282-x.
• [17]Wang YXJ,Huang H,Zheng CJ,et al.Diffusion-weighted MRI of the liver:challenges and some solutions for the quantification of apparent diffusion coefficient and intravoxel incoherent motion[J].Am J Nucl Med Mol Imaging,2021,11(2):107-142.
• [18]Surov A,Pech M,Omari J,et al.Diffusion-weighted imaging reflects tumor grading and microvascular invasion in hepatocellular carcinoma[J].Liver Cancer,2021,10(1):10-24.DOI:10.1159/000511384.
• [19]Messina C,Bignone R,Bruno A,et al.Diffusion-weighted imaging in oncology:an update[J].Cancers,2020,12(6):1493.DOI:10.3390/cancers12061493.
• [20]Park HJ,Kim YK,Park MJ,et al.Small intrahepatic mass-forming cholangiocarcinoma:target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma[J].Abdom Imaging,2013,38(4):793-801.DOI:10.1007/s00261-012-9943-x.
• [21]Fattach HE,Dohan A,Guerrache Y,et al.Intrahepatic and hilar mass-forming cholangiocarcinoma:qualitative and quantitative evaluation with diffusion-weighted MR imaging[J].Eur J Radiol,2015,84(8):1444-1451.DOI:10.1016/j.ejrad.2015.05.003.
• [22]Kim R,Lee JM,Shin CI,et al.Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging[J].Eur Radiol,2016,26(6):1808-1817.DOI:10.1007/s00330-015-4005-8.
• [23]Chang AI,Kim YK,Min JH,et al.Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI[J].Abdom Radiol (NY),2019,44(4):1395-1406.DOI:10.1007/s00261-018-1847-y.
• [24]Lewis S,Besa C,Wagner M,et al.Prediction of the histopathologic findings of intrahepatic cholangiocarcinoma:qualitative and quantitative assessment of diffusion-weighted imaging[J].Eur Radiol,2018,28(5):2047-2057.DOI:10.1007/s00330-017-5156-6.
• [25]Yamada S,Morine Y,Imura S,et al.Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma[J].J Hepatobiliary Pancreat Sci,2020,27(7):388-395.DOI:10.1002/jhbp.732.
• [26]Lee JS,Kim SH,Kang TW,et al.Mass-forming intrahepatic cholangiocarcinoma:diffusion-weighted imaging as a preoperative prognostic marker[J].Radiology,2016,281(1):119-128.DOI:10.1148/radiol.2016151781.
• [27]Sirica AE,Gores GJ.Desmoplastic stroma and cholangiocarcinoma:clinical implications and therapeutic targeting[J].Hepatology,2014,59(6):2397-2402.DOI:10.1002/hep.26762.
• [28]Zhou Y,Wang XL,Xu C,et al.Mass-forming intrahepatic cholangiocarcinoma:can diffusion-weighted imaging predict microvascular invasion?[J].J Magn Reson Imaging,2019,50(1):315-324.DOI:10.1002/jmri.26566.
• [29]Tsilimigras DI,Ejaz A,Cloyd J,et al.Tumor necrosis impacts prognosis of patients undergoing resection for T1 intrahepatic cholangiocarcinoma[J/OL].Ann Surg Oncol.2022.(2022-3-17)[2022-4-10].https://link.springer.com/article/10.1245/s10434-022-11462-y.DOI:10.1245/s10434-022-11462-y.
• [30]Sheng R,Huang X,Jin K,et al.Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma[J/OL].Eur Radiol.2022.(2022-3-17)[2022-4-10].https://link.springer.com/article/10.1007/s00330-022-08679-6.DOI:10.1007/s00330-022-08679-6.
• [31]Rimola J,Forner A,Sapena V,et al.Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma[J].Eur Radiol,2020,30(1):186-194.DOI:10.1007/s00330-019-06351-0.
• [32]Hwang J,Kim YK,Park MJ,et al.Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI[J].J Magn Reson Imaging,2012,36(4):881-889.DOI:10.1002/jmri.23728.
• [33]Choi SH,Lee SS,Kim SY,et al.Intrahepatic cholangiocarcinoma in patients with cirrhosis:differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT[J].Radiology,2017,282(3):771-781.DOI:10.1148/radiol.2016160639.
• [34]Jin KP,Sheng RF,Yang C,et al.Combined arterial and delayed enhancement patterns of MRI assist in prognostic prediction for intrahepatic mass-forming cholangiocarcinoma (IMCC)[J].Abdom Radiol (NY),2022,47(2):640-650.DOI:10.1007/s00261-021-03292-5.
• [35]Xu J,Igarashi S,Sasaki M,et al.Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers[J].Liver Int,2012,32(7):1156-1164.DOI:10.1111/j.1478-3231.2012.02783.x.
• [36]Huang B,Wu L,Lu XY,et al.Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging[J].Radiology,2016,281(1):150-157.DOI:10.1148/radiol.2016151205.
• [37]Kang Y,Lee JM,Kim SH,et al.Intrahepatic mass-forming cholangiocarcinoma:enhancement patterns on gadoxetic acid-enhanced MR images[J].Radiology,2012,264(3):751-760.DOI:10.1148/radiol.12112308.
• [38]Zhang XH,Huo L,Liu CF,et al.Arterial hyperenhancement of small intrahepatic cholangiocarcinomas correlates with microvessel counts and patient survival[J].HPB,2020,22(8):1197-1205.DOI:10.1016/j.hpb.2019.11.008.
• [39]Sheng RF,Zeng MS,Rao SX,et al.MRI of small intrahepatic mass-forming cholangiocarcinoma and atypical small hepatocellular carcinoma (≤3 cm) with cirrhosis and chronic viral hepatitis:a comparative study[J].Clin Imaging,2014,38(3):265-272.DOI:10.1016/j.clinimag.2013.12.022.
• [40]Min JH,Kim YK,Choi SY,et al.Intrahepatic mass-forming cholangiocarcinoma:arterial enhancement patterns at MRI and prognosis[J].Radiology,2019,290(3):691-699.DOI:10.1148/radiol.2018181485.
• [41]Teraoku H,Morine Y,Uyama N,et al.Role of central hypo-enhancement in the hepatic arterial phase of dynamic computed tomography in patients with mass-forming intrahepatic cholangiocarcinoma[J].World J Surg,2020,44(7):2350-2358.DOI:10.1007/s00268-020-05456-8.
• [42]Min JH,Lee MW,Park HS,et al.LI-RADS version 2018 targetoid appearances on gadoxetic acid-enhanced MRI:interobserver agreement and diagnostic performance for the differentiation of HCC and non-HCC malignancy[J/OL].AJR Am J Roentgenol.2022.(2022-3-23)[2022-4-10].https://www.ajronline.org/doi/10.2214/AJR.22.27380.DOI:10.2214/AJR.22.27380.
• [43]Li XQ,Wang X,Zhao DW,et al.Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma[J].World J Surg Oncol,2020,18(1):219.DOI:10.1186/s12957-020-01996-4.
• [44]Murakami T,Sofue K,Hori M.Diagnosis of hepatocellular carcinoma using Gd-EOB-DTPA MR imaging[J].Magn Reson Med Sci,2022,21(1):168-181.DOI:10.2463/mrms.rev.2021-0031.
• [45]Tseng TY,Tseng JH,Huang BS,et al.Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging[J].Abdom Radiol,2021,46(8):3995-4001.DOI:10.1007/s00261-021-03045-4.
• [46]Zhou N,Hu AN,Shi ZH,et al.Inter-observer agreement of computed tomography and magnetic resonance imaging on gross tumor volume delineation of intrahepatic cholangiocarcinoma:an initial study[J].Quant Imaging Med Surg,2021,11(2):579-585.DOI:10.21037/qims-19-1093.
• [47]Jeong HT,Kim MJ,Chung YE,et al.Gadoxetate disodium-enhanced MRIof mass-forming intrahepatic cholangiocarcinomas:imaging-histologic correlation[J].AJR Am J Roentgenol,2013,201(4):W603-W611.DOI:10.2214/AJR.12.10262.
• [48]Koh J,Chung YE,Nahm JH,et al.Intrahepatic mass-forming cholangiocarcinoma:prognostic value of preoperative gadoxetic acid-enhanced MRI[J].Eur Radiol,2016,26(2):407-416.DOI:10.1007/s00330-015-3846-5.
• [49]Chong YS,Kim YK,Lee MW,et al.Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI[J].Clin Radiol,2012,67(8):766-773.DOI:10.1016/j.crad.2012.01.004.
• [50]Min JH,Kim YK,Choi SY,et al.Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging:classification tree analysis applying capsule and septum[J].Eur J Radiol,2017,92:1-10.DOI:10.1016/j.ejrad.2017.04.008.
• [51]Asayama Y,Yoshimitsu K,Irie H,et al.Delayed-phase dynamic CTenhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma[J].Radiology,2006,238(1):150-155.DOI:10.1148/radiol.2381041765.
• [52]Ippolito D,Maino C,Pecorelli A,et al.Influence of injection rate in determining the development of artifacts during the acquisition of dynamic arterial phase in Gd-EOB-DTPA MRI studies[J].MAGMA,2021,34(1):133-140.DOI:10.1007/s10334-020-00857-1.
• [53]Chen BB,Lin ZZ,Shao YY,et al.Early changes in DCE-MRI biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure:two prospective phaseⅡtrials[J].Cancers,2021,13(19):4962.DOI:10.3390/cancers13194962.
• [54]Jarnagin WR,Schwartz LH,Gultekin DH,et al.Regional chemotherapy for unresectable primary liver cancer:results of a phaseⅡclinical trial and assessment of DCE-MRI as a biomarker of survival[J].Ann Oncol,2009,20(9):1589-1595.DOI:10.1093/annonc/mdp029.
• [55]Konstantinidis IT,Do RKG,Gultekin DH,et al.Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma:a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials[J].Ann Surg Oncol,2014,21(8):2675-2683.DOI:10.1245/s10434-014-3649-y.